Viridian Therapeutics (VRDN) News Today $16.62 +0.04 (+0.24%) Closing price 02/20/2025 04:00 PM EasternExtended Trading$16.87 +0.25 (+1.53%) As of 02/20/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Rice Hall James & Associates LLC Invests $1.02 Million in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Rice Hall James & Associates LLC bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 53,375 shares of the company's stock, valued at approximatelyFebruary 19 at 5:30 AM | marketbeat.comViridian Therapeutics (VRDN) Expected to Announce Quarterly Earnings on TuesdayViridian Therapeutics (NASDAQ:VRDN) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18 at 5:17 AM | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Trading Down 5% - Here's WhyViridian Therapeutics (NASDAQ:VRDN) Trading Down 5% - Here's WhyFebruary 12, 2025 | marketbeat.comViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 6, 2025 | businesswire.comViridian Therapeutics (NASDAQ:VRDN) Shares Down 5.8% - What's Next?Viridian Therapeutics (NASDAQ:VRDN) Stock Price Down 5.8% - Should You Sell?February 5, 2025 | marketbeat.comSG Americas Securities LLC Has $596,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)SG Americas Securities LLC lifted its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 89.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,085 shares of the company's stoJanuary 31, 2025 | marketbeat.comShort Interest in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Grows By 28.9%Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 12,050,000 shares, an increase of 28.9% from the December 31st total of 9,350,000 shares. Based on an average daily trading volume, of 1,290,000 shares, the short-interest ratio is currently 9.3 days.January 30, 2025 | marketbeat.comMoody Aldrich Partners LLC Takes $1.13 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Moody Aldrich Partners LLC bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 58,688 shares of the company'sJanuary 30, 2025 | marketbeat.comEquities Analysts Issue Forecasts for VRDN Q1 EarningsViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Viridian Therapeutics in a research note issued to investors on Monday, January 27th. Leerink Partnrs analyst T. Smith expects that the company will post eaJanuary 29, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twelve brokerages that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation aJanuary 29, 2025 | marketbeat.comViridian Therapeutics Primed for Market Domination with Promising Veligrotug Results and Strategic PositioningJanuary 28, 2025 | markets.businessinsider.comLeerink Partnrs Weighs in on VRDN FY2029 EarningsViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Investment analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of Viridian Therapeutics in a research report issued to clients and investors on Monday, January 27th. Leerink Partnrs analyst T. SmitJanuary 28, 2025 | marketbeat.comViridian Metals becomes top claim holder in Newfoundland and LabradorJanuary 24, 2025 | msn.comViridian Therapeutics (NASDAQ:VRDN) Trading Up 6.3% - What's Next?Viridian Therapeutics (NASDAQ:VRDN) Shares Up 6.3% - Time to Buy?January 17, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Short Interest Up 28.9% in DecemberViridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 12,050,000 shares, an increase of 28.9% from the December 15th total of 9,350,000 shares. Based on an average trading volume of 1,290,000 shares, the days-to-cover ratio is presently 9.3 days.January 16, 2025 | marketbeat.comViridian Therapeutics: Promising Market Position with Superior Efficacy and Safety of Veligrotug in TED TreatmentJanuary 15, 2025 | markets.businessinsider.comJPMorgan Chase & Co. Purchases 274,641 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)JPMorgan Chase & Co. boosted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 218.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 400,351 shares of the company's stock after purJanuary 14, 2025 | marketbeat.comViridian Therapeutics: Strategic Positioning and First-Mover Advantage in the TED MarketJanuary 9, 2025 | markets.businessinsider.comViridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye DiseaseJanuary 8, 2025 | finance.yahoo.comViridian Therapeutics: Strategic Positioning and Promising Data Justify Buy RatingJanuary 8, 2025 | markets.businessinsider.comViridian Therapeutics: Promising Pipeline and Strong Financials Justify Buy RatingJanuary 7, 2025 | markets.businessinsider.comPositive Outlook for Viridian Therapeutics: Analyst Reaffirms Buy Rating on Strong Competitive Position and Efficacy of VRDN-001January 7, 2025 | markets.businessinsider.comViridian Therapeutics (NASDAQ:VRDN) Shares Up 5.8% - Here's WhyViridian Therapeutics (NASDAQ:VRDN) Shares Up 5.8% - Should You Buy?January 7, 2025 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday.January 7, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have earned an average rating of "Moderate Buy" from the twelve brokerages that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and nine have aJanuary 4, 2025 | marketbeat.comPrincipal Financial Group Inc. Acquires 162,665 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Principal Financial Group Inc. grew its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 1,603.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 172,810 shares of the company's stock after purchasing aJanuary 3, 2025 | marketbeat.comGeode Capital Management LLC Has $33.98 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Geode Capital Management LLC raised its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 5.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,493,311 shares of the company'December 26, 2024 | marketbeat.comIs Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$19.3 Based On Its Intrinsic Value?December 25, 2024 | finance.yahoo.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Barclays PLCBarclays PLC grew its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 113.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 125,397 shares of the company's stock after purchasing an additional 66,550 shares duDecember 25, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Trading Down 3.4% - Should You Sell?Viridian Therapeutics (NASDAQ:VRDN) Stock Price Down 3.4% - Time to Sell?December 24, 2024 | marketbeat.comWells Fargo Downgrades Viridian Therapeutics (VRDN)December 20, 2024 | msn.comViridian Therapeutics downgraded to Equal Weight from Overweight at Wells FargoDecember 19, 2024 | markets.businessinsider.comViridian Therapeutics (NASDAQ:VRDN) Shares Gap Down - Time to Sell?Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Down - What's Next?December 19, 2024 | marketbeat.comViridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)December 19, 2024 | seekingalpha.comWells Fargo & Company Reaffirms Equal Weight Rating for Viridian Therapeutics (NASDAQ:VRDN)Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $27.00 target price on shares of Viridian Therapeutics in a report on Thursday.December 19, 2024 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by State Street CorpState Street Corp reduced its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 14.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,379,774 shares of the company's stock aftDecember 19, 2024 | marketbeat.comBuy Rating Reaffirmed for Viridian Therapeutics: Promising Phase 3 Results for Veligrotug in TED TreatmentDecember 18, 2024 | markets.businessinsider.comViridian Therapeutics: Veligrotug De-Risked In TED With Hints Of DifferentiationDecember 18, 2024 | seekingalpha.comTD Cowen Remains a Buy on Viridian Therapeutics (VRDN)December 18, 2024 | markets.businessinsider.comBreaking Down Viridian Therapeutics: 10 Analysts Share Their ViewsDecember 18, 2024 | benzinga.comViridian Therapeutics (VRDN) Gets a Buy from OppenheimerDecember 18, 2024 | markets.businessinsider.comViridian Therapeutics (NASDAQ:VRDN) Shares Down 5.7% - Time to Sell?Viridian Therapeutics (NASDAQ:VRDN) Trading Down 5.7% - Here's WhyDecember 17, 2024 | marketbeat.comViridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)December 17, 2024 | seekingalpha.comViridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $47.00 at Royal Bank of CanadaRoyal Bank of Canada lifted their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a research report on Tuesday.December 17, 2024 | marketbeat.comViridian Therapeutics’ Veligrotug Outperforms in THRIVE-2 Trial, Boosting Buy RatingDecember 17, 2024 | markets.businessinsider.comLord Abbett & CO. LLC Purchases New Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Lord Abbett & CO. LLC acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 391,958 shares of the company's stock, valued at approximately $8,917,000. Lord AbbettDecember 17, 2024 | marketbeat.comWellington Management Group LLP Cuts Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Wellington Management Group LLP cut its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 16.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 235,987 shares of the company's stock after selling 48,057 shares during the period. WellingtDecember 17, 2024 | marketbeat.comViridian Therapeutics’ Veligrotug: Promising Phase 3 Results and Strong Buy RatingDecember 16, 2024 | markets.businessinsider.comViridian Therapeutics Stock Hits 3-Week High, Retail Buzz Builds On Chronic Thyroid Eye Disease Trial DataDecember 16, 2024 | msn.comViridian stock soars 25% on Phase 3 data for veligrotugDecember 16, 2024 | msn.com Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address VRDN Media Mentions By Week VRDN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRDN News Sentiment▼0.860.60▲Average Medical News Sentiment VRDN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRDN Articles This Week▼25▲VRDN Articles Average Week Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RDNT News Today BTSG News Today SHC News Today SGRY News Today VCYT News Today LFST News Today PRVA News Today CON News Today TDOC News Today ARDT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRDN) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
